VERA Vera Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1831828 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-64.8%
TTM EPS YoY-47.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-113.5%
ROA-84.5%
ROIC (approx.)-87.8%
Asset turnover—
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.23x
Current ratio7.91x
Interest coverage-57.40x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $215.26M | $126.17M |
| SG&A expense | $100.22M | $41.00M |
| Operating income | -$315.47M | -$167.17M |
| Interest expense | $7.53M | $7.63M |
| Pretax income | -$299.61M | -$152.15M |
| Income tax | $1,000 | $1,000 |
| Net income | -$299.62M | -$152.15M |
| EBITDA | -$315.00M | -$167.06M |
| EPS (basic) | -4.66 | -2.75 |
| EPS (diluted) | -4.66 | -2.75 |
| Weighted avg. shares (diluted) | 64.23M | 55.33M |
| Balance sheet | ||
| Cash & equivalents | $354.73M | $92.65M |
| Short-term investments | $359.86M | $548.21M |
| Receivables | $0 | — |
| Inventory | $0 | — |
| Current assets | $728.88M | $651.22M |
| PP&E, net | $1.37M | $960,000 |
| Intangibles | $0 | — |
| Total assets | $734.73M | $655.68M |
| Current liabilities | $53.45M | $25.37M |
| Long-term debt | $74.84M | $50.69M |
| Total debt | $74.84M | $50.69M |
| Total liabilities | $130.21M | $78.53M |
| Shareholders' equity | $604.52M | $577.15M |
| Net debt | -$279.89M | -$41.96M |
| Cash flow statement | ||
| Operating cash flow | -$241.10M | -$134.68M |
| Capital expenditure | $630,000 | $972,000 |
| Free cash flow | -$241.73M | -$135.65M |
| Investing cash flow | $194.29M | -$425.03M |
| Financing cash flow | $308.90M | $606.67M |
| Depreciation & amortization | $468,000 | $105,000 |
| Stock-based compensation | $37.93M | $20.80M |
| Share buybacks | $0 | $13,000 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.